Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
For most researchers, lyophilized powder offers better value and quality control despite the inconvenience of reconstitution
Srensen, G., Gasbjerg, L
Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals
Patients taking insulin or sulfonylureas should monitor their blood glucose more frequently when reducing meal sizes, as the risk of hypoglycaemia may increase
The sacroiliac joints are some of the biggest joints in your body, and you use them every time you move or shift your hips
Stable lyophilizate, no caking
